Drug Trial Radar · NCT07631871
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
May 12, 2026
Primary completion
Dec 31, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Haihua YuanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if Zanidatamab can treat HER2-positive advanced tumors in adults. The main question it aims to answer is: What is the objective response rate of Zanidatamab in adult patients with HER-2 positive advanced solid tumors? Participants will receive Zanidatamab intravenously on Day 1 of each 2-week treatment cycle. The dosage is 20 mg/kg per cycle.
Conditions
- Neoplasms
- Solid Tumors
- HER2 Positive Solid Tumor
- Endometrial Neoplasm
- Urothelial Carcinoma (UC)
- Pancreatic Neoplasms
- Colorectal Neoplasms
- Head and Neck Neoplasms
- Cervical Neoplasms
- Ovarian Neoplasms
Interventions
ZanidatamabDrug
Treatment continues until disease progression, intolerable toxicity, subject withdrawal or study termination.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate, ORRTime frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 24months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.